^
Association details:
| Biomarker: | B2M mutation |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
Excerpt:
A total of 192 plasma samples from 75 patients with r/r cHL were collected at baseline and upon therapeutic evaluation...the mutations of B2M, TNFRSF14 and KDM2B were found to be associated with acquired resistance.
DOI:
10.1016/j.ebiom.2020.102731
